This International Alliance for Biological Standardization COVID-19 webinar was organized to provide an update on the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2, none months after COVID-19 was declared a public health emergency of international concern. It brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable delegation from low- and middle-income countries. Highlights • Recombination probably led to a virus that acquired human-to-human transmissibility. • Initially, SARS-CoV-2 infection in the second wave was mistakenly interpreted as more benign. • Neutralizing antibodies likely contribute to control of SARS-CoV-2 disease. • A mucosal immune response (IgA in nasal mucus or saliva) may be a useful correlate of protection. • COVAX aims to deliver 2 billion doses of vaccine by the end of 2021, to all the countries around the world.
【저자키워드】 immunology, SARS-CoV-2, Vaccine, Virology, Epidemiology, 【초록키워드】 COVID-19, immunology, Saliva, Vaccine development, Virology, Neutralizing antibodies, antibody, SARS-COV-2 infection, nasal, virus, Transmissibility, IgA, International, Recombination, second wave, public health emergency, dose, COVAX, Biological, Biological Standardization, SARS-CoV-2 disease, Highlights, mucosal immune, country, contribute, the vaccine, Alliance, Initially, organized, 【제목키워드】 pandemic, nine,